Cidara Therapeutics Inc (CDTX) — Cash Flow-to-Debt Ratio
Cidara Therapeutics Inc (CDTX) has a Cash Flow-to-Debt Ratio of -0.42x as of September 2025, meaning its operating cash flow of $-40.62 Million could theoretically repay 0% of its total liabilities ($96.26 Million) in one year. See Cidara Therapeutics Inc (CDTX) flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cidara Therapeutics Inc Cash Flow-to-Debt Ratio (2013–2024)
Historical debt coverage capacity for Cidara Therapeutics Inc across 12 annual periods. For the full cash flow conversion analysis, see how efficiently does Cidara Therapeutics Inc generate cash.
Annual Cash Flow-to-Debt Ratio for Cidara Therapeutics Inc (2013–2024)
Year-by-year debt coverage analysis for Cidara Therapeutics Inc. Check CDTX cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -3.43x | $-176.53 Million | $51.49 Million | ▼ -1050.0% |
| 2023 | -0.30x | $-22.43 Million | $75.24 Million | ▲ +35.2% |
| 2022 | -0.46x | $-28.47 Million | $61.92 Million | ▲ +2.0% |
| 2021 | -0.47x | $-25.23 Million | $53.75 Million | ▲ +57.1% |
| 2020 | -1.09x | $-54.41 Million | $49.71 Million | ▼ -19.5% |
| 2019 | -0.92x | $-28.53 Million | $31.14 Million | ▲ +67.7% |
| 2018 | -2.84x | $-56.70 Million | $19.97 Million | ▼ -9.7% |
| 2017 | -2.59x | $-49.91 Million | $19.29 Million | ▼ -22.2% |
| 2016 | -2.12x | $-39.77 Million | $18.78 Million | ▲ +50.6% |
| 2015 | -4.28x | $-25.96 Million | $6.06 Million | ▼ -80.3% |
| 2014 | -2.37x | $-7.71 Million | $3.25 Million | ▼ -262.3% |
| 2013 | -0.66x | $-1.05 Million | $1.60 Million | — |